Therapeutic Compounds

A method of treatment or prophylaxis of an infection caused by a pathogen in a patient in need of the same, which method comprises oral or intravenous administration to the patient an effective amount of a compound of formula (I)

• wherein
• Q represents —COOH, —COOR5, or a pharmaceutically acceptable salt of —COOH;
• R1 represents an unsubstituted aryl group, hydrogen, a linear or branched unsubstituted or substituted saturated or unsaturated alkyl group with 1 to 10 carbon atoms, halide, amino, hydroxyl, carbonyl, or a substituted aryl group;
• R2a, R2b, R3a, R3b, R4a and R4b, if present, each independently represent hydrogen, halide, amino, hydroxyl, carbonyl, a linear or branched substituted or unsubstituted saturated or unsaturated alkyl group with 1 to 10 carbon atoms, or a substituted or unsubstituted aryl group;
• and/or R3a, together with an adjacent R4a or R2a, may represent a carbon-carbon π bond;
• and/or
• R3b, together with an adjacent R4b or R2b, may represent a carbon-carbon π bond;
• m and n are each independently 0 or 1;
• R5, if present, represents a linear or branched substituted or unsubstituted saturated or unsaturated alkyl group with 1 to 10 carbon atoms, a substituted or unsubstituted aryl group, a triglyceride moiety —CH2CH(OC(═O)R6)CH2(OC(═O)R7), or a diglyceride moeity —C(C═O)OCH2CH(OC(═O)R6)CH2OH or a salt thereof;
• and
• R6 and R7, if present, independently represent hydrogen, a linear or branched substituted or unsubstituted saturated or unsaturated alkyl group with 1 to 10 carbon atoms or a substituted or unsubstituted aryl group.
• wherein:
• (i) said infection is selected from infection of the lung, trachea, urinary tract or kidney, upper GI tract and\or blood
• and\or
• (ii) said pathogen is selected from:
• Mycobacterium tuberculosis;
• Pseudomonas bacteria;
• Haemophilus influenzae;
• Moraxella catarrhalis;
• and in each case wherein the effective amount is an oral dose of between 500 and 4000 mg/day, or an intravenous dose of between 200 and 1000 mg/day such as to boost innate antimicrobial activity in the patient